Redhill Biopharma Stock News

 RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea  RedHill to receive $1.5 million upfront and is eligible for up to $5.6 million in milestone payments in addition to royalties on net sales from Kukbo--Opaganib's Phase 2/3 clinical data shows improved viral RNA clearance, reduced mortality on top of remdesivir & corticosteroids and faster time to recovery for moderate to severe hospitalized COVID-19 patients treated with opaganib; potent in vitro inhibition of multiple v...

TEL AVIV, Israel and RALEIGH, NC , March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it wil

RedHill Biopharma Ltd (NASDAQ: RDHL ) has announced topline results from the Phase 2 part of the Phase 2/3 study of RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients. The study showed promising efficacy results delivering a 100% reduction in hospitalization due to COVID-19, with zero patients on … Full story available on Benzinga.com

RedHill Biopharma''s (RDHL) oral COVID-19 treatment RHB-107 (upamostat) demonstrated a significant reduction in new severe symptoms in non-hospitalized, symptomatic COVID patients.

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19  Phase 2 part of Phase 2/3 study of once-daily oral RHB-107 in symptomatic COVID-19 successfully met the study's primary endpoint showing good safety and tolerability and highly promising efficacy results--100% reduction in hospitalization due to COVID-19 with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized on the placebo-controlled arm--87.8% reduction in reported new severe C...

RedHill Biopharma <> expects Q4 total net revenues to be in the range of $22M to-24M, below the consensus revenue estimate of $24.09M, according to preliminary data.The company…

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven Business update (unaudited and preliminary estimated fourth quarter financial data[1]): Record Q4/2021 total net revenues estimated to be in the range of $22-24 million vs. $21.6 million in Q3/2021 and $21.5 in Q4/2020 Estimated to have achieved commercial operations breakeven in Q4/2021 and expect profitable commercial operations in 2022 (both non-GAAP EBITDA)[2]  Cash balance[3] of $54.2 million as...

TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided a business update for the fourth quarter of 2021, including certain estimated unaudited preliminary…

RedHill Biopharma Ltd. (NASDAQ:RDHL) price closed lower on Monday, February 07, dropping -5.53% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

RedHill Biopharma Ltd (NASDAQ: RDHL ) has announced results from two recently completed prespecified analyses from the oral opaganib Phase 2/3 study in hospitalized severe COVID-19. The first analysis showed that opaganib significantly reduced mortality when given to patients who received Gilead Science Inc''s (NASDAQ: GILD ) remdesivir and corticosteroids, the best available standard-of-care (SoC) for hospitalized patients. A second … Full story available on Benzinga.com

Announcing data from a Phase 2/3 trial for its COVID-19 therapy opaganib, RedHill Biopharma <> said Monday that the oral treatment “significantly reduced” death among…

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19 Updates on Regulatory Discussions and Plans in Multiple Countries  Prespecified analysis of Phase 2/3 opaganib data in severe COVID-19 patients showed a significant, 70.2% mortality benefit with opaganib by Day 42 when given on top of the best available standard-of-care (SoC), remdesivir and corticosteroids (6.98% mortality in the opaganib arm versus 23.4% for placebo, p-v...

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results from two…

Popular penny stocks on Reddit today. Are they a buy? The post 3 Top Penny Stocks To Watch As Redditors Buy The Dip appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com

RedHill Biopharma (RDHL) announced that its oral COVID-19 therapy opaganib “significantly” improved viral clearance in a Phase 2/3 trial involving severely ill hospitalized patients…